Experts spotlight the prostate and bladder cancer presentations they're most excited to see at the 2026 ESMO Congress.
News|Articles|February 12, 2025
Oncology Experts Preview Top Abstracts From 2025 ASCO GU
Author(s)Kristi Rosa
Fact checked by: Chris Ryan
Experts highlight the top presentations to watch for at the 2025 Genitourinary Cancers Symposium.
Advertisement
Advertisement
Ahead of this year’s Genitourinary Cancers Symposium, OncLive® asked leading oncologists in the space to share what presentations they are most excited to learn more about during the meeting and why.
Related to this article
Patients with resected RCC given adjuvant durvalumab with or without tremelimumab described persistent low-grade toxicities as most disruptive to QOL.
First-line IO-based combination regimens were increasingly used and associated with longer observed survival in advanced renal cell carcinoma.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The FDA accepted an NDA for UGN-103 for recurrent low-grade intermediate-risk NMIBC, with a target action date of June 14, 2027.
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
Advertisement
Advertisement